<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BioDrugs</journal-id><journal-id journal-id-type="iso-abbrev">BioDrugs</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Biodrugs</journal-title></journal-title-group><issn pub-type="ppub">1173-8804</issn><issn pub-type="epub">1179-190X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11906553</article-id><article-id pub-id-type="pmcid-ver">PMC11906553.1</article-id><article-id pub-id-type="pmcaid">11906553</article-id><article-id pub-id-type="pmcaiid">11906553</article-id><article-id pub-id-type="pmid">39875705</article-id><article-id pub-id-type="doi">10.1007/s40259-025-00705-5</article-id><article-id pub-id-type="publisher-id">705</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2955-458X</contrib-id><name name-style="western"><surname>Yu</surname><given-names initials="S">Sebastian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8285-1700</contrib-id><name name-style="western"><surname>Huo</surname><given-names initials="AP">An-Ping</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="YH">Yu-Hsun</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1235-0679</contrib-id><name name-style="western"><surname>Wei</surname><given-names initials="JCC">James Cheng-Chung</given-names></name><address><email>jccwei@gmail.com</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03gk81f96</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution>Department of Dermatology, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03gk81f96</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution>Department of Dermatology, </institution><institution>Kaohsiung Medical University Gangshan Hospital, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02xmkec90</institution-id><institution-id institution-id-type="GRID">grid.412027.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0620 9374</institution-id><institution>Department of Dermatology, </institution><institution>Kaohsiung Medical University Hospital, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05bqach95</institution-id><institution-id institution-id-type="GRID">grid.19188.39</institution-id><institution-id institution-id-type="ISNI">0000 0004 0546 0241</institution-id><institution>Master of Public Health Program, College of Public Health, </institution><institution>National Taiwan University, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/059ryjv25</institution-id><institution-id institution-id-type="GRID">grid.411641.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0532 2041</institution-id><institution>Institute of Medicine, </institution><institution>Chung Shan Medical University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01abtsn51</institution-id><institution-id institution-id-type="GRID">grid.411645.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0638 9256</institution-id><institution>Department of Allergy, Immunology and Rheumatology, South District, </institution><institution>Chung Shan Medical University Hospital, </institution></institution-wrap>No. 110, Sec. 1, Jianguo N. Rd, Taichung City, 40201 Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/059ryjv25</institution-id><institution-id institution-id-type="GRID">grid.411641.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0532 2041</institution-id><institution>School of Medicine, </institution><institution>Chung Shan Medical University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01abtsn51</institution-id><institution-id institution-id-type="GRID">grid.411645.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0638 9256</institution-id><institution>Department of Medical Research, </institution><institution>Chung Shan Medical University Hospital, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/059ryjv25</institution-id><institution-id institution-id-type="GRID">grid.411641.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0532 2041</institution-id><institution>Department of Nursing, </institution><institution>Chung Shan Medical University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032d4f246</institution-id><institution-id institution-id-type="GRID">grid.412449.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9678 1884</institution-id><institution>Graduate Institute of Integrated Medicine, </institution><institution>China Medical University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038a1tp19</institution-id><institution-id institution-id-type="GRID">grid.252470.6</institution-id><institution-id institution-id-type="ISNI">0000 0000 9263 9645</institution-id><institution>Office of Research and Development, </institution><institution>Asia University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0265d1010</institution-id><institution-id institution-id-type="GRID">grid.263452.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 4018</institution-id><institution>Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, </institution><institution> Third Hospital of Shanxi Medical University, </institution></institution-wrap>Taiyuan, Shanxi China </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>39</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">484214</issue-id><fpage>297</fpage><lpage>306</lpage><history><date date-type="accepted"><day>12</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>15</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-15 00:25:32.953"><day>15</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40259_2025_Article_705.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Psoriatic arthritis (PsA) is a common comorbidity in patients with psoriasis (PsO) that leads to significant disease burden. Biologic therapies targeting the interleukin (IL)-23/IL-17 axis have been widely used for PsO, but their comparative effectiveness in preventing PsA remains unclear.</p></sec><sec><title>Objective</title><p id="Par2">The study objective was to compare the occurrence of developing incidental PsA among PsO patients treated with interleukin-23 inhibitors (IL23is) or interleukin-17 inhibitors (IL17is).</p></sec><sec><title>Methods</title><p id="Par3">A retrospective cohort study was conducted using real-world data from the TriNetX US Collaborative Network, including 53 healthcare organizations. Adult PsO patients treated with IL23is or IL17is between January 2019 and June 2022 were identified. Cox regression analysis was used to assess the risk of PsA incidence, with hazard ratios (HRs) and 95% confidence intervals (CIs) reported. Subgroup analyses were performed based on age, sex, and ethnicity. Sensitivity analyses included comparisons with tumor necrosis factor (TNF) inhibitors (TNFis) to ensure robustness.</p></sec><sec><title>Results</title><p id="Par4">A total of 4,580 PsO patients were included in the study, with 2,273 receiving IL23is and 2,307 receiving IL17is. Treatment with IL23is was associated with a significantly lower incidence of PsA compared to IL17is (HR = 0.60, 95% CI 0.44&#8211;0.82, <italic toggle="yes">P</italic> = 0.001). This reduction in risk was particularly notable in the 41- to 65-year age group (HR = 0.42, 95% CI 0.27&#8211;0.64, <italic toggle="yes">P</italic> &lt; 0.001) and among females (HR = 0.57, 95% CI 0.38&#8211;0.86, <italic toggle="yes">P</italic> = 0.007). Subgroup analyses based on ethnicity revealed varying outcomes, with White patients showing a significant risk reduction (HR = 0.55, 95% CI 0.38&#8211;0.79, <italic toggle="yes">P</italic> = 0.001) but no significant risk reduction was observed in Black or African American patients (HR = 1.37, 95% CI 0.37&#8211;5.13, <italic toggle="yes">P</italic> = 0.637). Sensitivity analyses comparing IL23is and TNFis confirmed the robustness of the findings.</p></sec><sec><title>Conclusion</title><p id="Par5">IL23is are associated with a lower risk of PsA incidence compared to IL17is in PsO patients, particularly in specific age, sex, and ethnic groups. These findings suggest that IL23is may be more suitable for PsO patients at high risk of PsA and could inform potential updates to treatment guidelines. Further research should focus on refining therapeutic strategies by incorporating patient-specific factors such as comorbidities, ethnicity, and genetic predispositions, which could optimize biologic selection and enhance PsA prevention efforts in clinical practice.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40259-025-00705-5.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100020595</institution-id><institution>National Science and Technology Council</institution></institution-wrap></funding-source><award-id>NSTC-111-2314-B-037-042</award-id><award-id>NSTC-112-2221-E-020-005</award-id><award-id>NSTC-113-2314-B-037-076-MY3</award-id><principal-award-recipient><name name-style="western"><surname>Yu</surname><given-names>Sebastian</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d33e368"><title>Key Points</title><p id="Par6">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">This study shows that PsO patients treated with IL-23 inhibitors (IL23is) had a significantly lower risk of developing incidental psoriatic arthritis (PsA) compared to PsO patients treated with IL-17 inhibitors (IL17is), as indicated by a hazard ratio of 0.60 (<italic toggle="yes">P</italic> = 0.001).</td></tr><tr><td align="left" colspan="1" rowspan="1">Subgroup analyses revealed that the reduced PsA risk with IL23is was more pronounced in patients aged 41&#8211;65 years (HR = 0.42, <italic toggle="yes">P</italic> &lt; 0.001) and females (HR = 0.57, <italic toggle="yes">P</italic> = 0.007), while other age groups showed varying degrees of risk reduction.</td></tr><tr><td align="left" colspan="1" rowspan="1">The study highlighted varying PsA risks across ethnic groups, with White (HR = 0.55, <italic toggle="yes">P</italic> = 0.001) and Asian (HR = 0.37, <italic toggle="yes">P</italic> = 0.125) patients showing a lower risk, while Black or African American patients did not demonstrate a significant reduction (HR = 1.37, <italic toggle="yes">P</italic> = 0.637).</td></tr><tr><td align="left" colspan="1" rowspan="1">These findings suggest that IL23is may be a more suitable treatment option for patients with PsO at higher risk of PsA, particularly within certain demographic and ethnic groups, and support the need for tailored treatment plans and potential updates to current treatment guidelines.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1"><title>Introduction</title><p id="Par7">Psoriasis (PsO) is an immune-mediated, chronic, inflammatory disease that mainly affects the skin and joints [<xref ref-type="bibr" rid="CR1">1</xref>]. Systemic inflammation of psoriasis can involve other organs and a variety of comorbidities have been reported, including cardiovascular diseases [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], metabolic syndrome [<xref ref-type="bibr" rid="CR4">4</xref>], chronic kidney disease [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], and psychiatric diseases [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>], among others. The economic burden of PsO has been increasing in the USA and globally in the past two decades [<xref ref-type="bibr" rid="CR10">10</xref>]. A higher economic burden of PsO is not limited to skin and includes their comorbidities, including psoriatic arthritis (PsA) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Psoriatic patients with comorbid PsA have higher comorbidity and healthcare utilization and costs [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. To optimize patient outcomes, it is critical to meticulously assess the differential efficacy of existing therapies for PsO, PsA, and associated comorbidities. Such a comprehensive evaluation will enable the development of tailored, holistic care plans for individuals suffering from PsO [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par8">The interleukin (IL)&#8208;23/IL&#8208;17 immunologic axis plays a central role in the pathogenesis of PsO and PsA [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>]. The debate over which treatment is better for psoriatic disease, IL-17 inhibitors (IL17is) or IL-23 inhibitors (IL23is), began with the ECLIPSE clinical trial [<xref ref-type="bibr" rid="CR19">19</xref>]. That phase 3 randomized controlled trial showed that secukinumab had an earlier onset by week 8 while guselkumab showed superior long-term efficacy based on PASI 90 at week 48 [<xref ref-type="bibr" rid="CR19">19</xref>]. A real-world data study showed that there was no significant statistical disparity observed in the effectiveness of IL23is versus IL17is, both in bio-na&#239;ve patients and as a secondary therapeutic option following unsuccessful treatment with either a biosimilar or the original adalimumab formulation [<xref ref-type="bibr" rid="CR20">20</xref>]. However, the lack of statistical significance reported in a previous study could be due to its small sample size [<xref ref-type="bibr" rid="CR15">15</xref>]. Other retrospective studies also did not demonstrate differences between IL23is and IL17is in their cohorts [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Additionally, the EULAR recommendations should be emphasized as they highlight the limitations of retrospective studies [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Therefore, further investigations in real-world settings with a larger sample size are warranted to compare the effectiveness of IL23is and IL17is in controlling PsO.</p><p id="Par9">Another significant clinical issue is whether IL-23i or IL-17i can prevent incidental PsA in patients with PsO. Although recent studies showed that IL23is significantly outperformed placebo in treating PsA [<xref ref-type="bibr" rid="CR25">25</xref>], evidence regarding whether IL23is can prevent PsA is still limited [<xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref>]. By utilizing the extensive data from the Global Collaborative Network in the TriNetX database, Singla et al. compared treatments with IL-23i, IL-12/23i, IL-17i, or tumor necrosis factor (TNF) inhibitors (TNFis) to reduce the onset of PsA in PsO patients and found that IL-23i and IL-12/23i, but not IL-17i, were more effective in reducing the incidental onset of PsA in PsO patients compared to TNFis [<xref ref-type="bibr" rid="CR29">29</xref>]. However, no study has focused on differences in the risk of PsA occurrence between IL-23i or IL-17i treatment in PsO patients. Therefore, this investigation was designed to compare IL23is with IL17is in reducing the incidence of PsA among patients with PsO. The emphasis of this study on a substantial and varied patient cohort offers critical insights, potentially influencing the development of more efficacious treatment approaches for PsA.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data Source</title><p id="Par10">This study was conducted as a retrospective cohort study. The data used for this study were obtained from TriNetX, a global health research network that allows access to electronic medical records from various healthcare organizations (HCOs). These records include information such as diagnoses, procedures, medications, laboratory values, and genomic data. TriNetX follows a standardized framework to assess the quality of the data, focusing on conformance, completeness, and plausibility. The TriNetX Research Network datasets have been widely utilized in epidemiological studies [<xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR32">32</xref>]. The data extraction and analysis were conducted in October 2022 using the US Collaborative Network, which is a subset of the TriNetX network consisting of 53 HCOs. The study period was limited to 1 January 2019, to 30 June 2022. These records include laboratory data, body mass index (BMI), diagnoses, and prescribed medications. All data provided by the TriNetX platform were de-identified in accordance with the standards outlined in section &#167;164.514(a) of the HIPAA Privacy Rule. The de-identification process is validated by a qualified expert, as defined in Section &#167;164.514(b)(1) of the HIPAA Privacy Rule. This formal determination, which was updated in December 2020, replaces the previous waiver granted by the Western Institutional Review Board (WIRB).</p><p id="Par11">TriNetX obtained a waiver from the WIRB due to its provision of aggregated counts and statistical summaries of de-identified data, adhering to the de-identification standards specified in Section &#167;164.514(a) of the HIPAA Privacy Rule. As an HCO member of TriNetX, Chung Shan Medical University Hospital (CSMUH) can access the de-identified data in the TriNetX platform. This study was approved by Chung Shan Medical University Hospital Institutional Review Board (IRB NO: CS2-21176).</p></sec><sec id="Sec4"><title>Subject Selection</title><p id="Par12">The study included participants who were 18 years or older and had received a new diagnosis of PsO on or before 30 June 2022. The diagnosis was confirmed based on the prescription of specific medications, including TNF inhibitors (TNFis) (such as etanercept, adalimumab, golimumab, and infliximab), IL17is (such as secukinumab, ixekizumab, and brodalumab), or IL23is (risankizumab, guselkumab). The PsO cohort was divided into two groups: IL17is or IL23is, from the day of PsO diagnosis to 3 months afterward. Individuals who were on different drugs within the same drug class were excluded from the study. Previous exposure to IL23is or TNFis was excluded in the IL17i group, and previous exposure to IL17is or TNFis was excluded in the IL23i group. All cohorts defined the index day as 3 months after the PsO diagnosis. Participants with a history of cerebrovascular disease, depression, PsA, or cancer before the index day were excluded from the study. To ensure a fair comparison, the IL17i cohort was matched 1:1 with the IL23i cohort based on age, sex, race, BMI, smoking behavior, and socioeconomic status.</p><p id="Par13">Pre-existing comorbidities considered before the index day included diabetes mellitus, gout, myelofibrosis, hyperuricemia, and lipid disorders. Follow-up of all cohorts continued until the occurrence of PsA, withdrawal from the TriNetX database, death, or the study&#8217;s conclusion on 19 August 2023.</p></sec><sec id="Sec5"><title>Sensitivity Analysis</title><p id="Par14">To ensure the robustness of the results, this study introduced a control group using TNFis medications. IL-23i (risankizumab, guselkumab) or TNFis (etanercept, adalimumab, golimumab, infliximab) were defined as being used within 3 months of a PsO diagnosis, excluding those with the concurrent use of other medications. PsA was defined as occurring at least 3 months after the PsO diagnosis.</p></sec><sec id="Sec6"><title>Statistical Analysis</title><p id="Par15">Baseline characteristics and comorbidities for all cohorts were analyzed first (Table <xref rid="Tab1" ref-type="table">1</xref>). To rigorously calculate the risk of PsA, the study used the propensity score matching with age, sex, race, BMI, smoking behavior, and socioeconomic status, after matching the Cox regression hazards model to calculate the hazard ratios (HRs), and p-values were determined by log-rank test. All data management and HR calculations were done using the TriNetX system. Table <xref rid="Tab1" ref-type="table">1</xref> in the Online Supplementary Material (OSM) lists the codes for variables used in this study to ensure consistency and reproducibility of the data analysis.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of the IL17i and IL23i cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="3" rowspan="1">Unmatched</th><th align="left" colspan="3" rowspan="1">Matched</th></tr><tr><th align="left" colspan="1" rowspan="1">IL23is, <italic toggle="yes">N</italic> = 2273</th><th align="left" colspan="1" rowspan="1">IL17is, <italic toggle="yes">N</italic> = 2307</th><th align="left" colspan="1" rowspan="1">SD</th><th align="left" colspan="1" rowspan="1">IL23is, <italic toggle="yes">N</italic> = 2088</th><th align="left" colspan="1" rowspan="1">IL17is, <italic toggle="yes">N</italic> = 2088</th><th align="left" colspan="1" rowspan="1">SD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, y</td><td align="left" colspan="1" rowspan="1">46.6&#177;15.2</td><td align="left" colspan="1" rowspan="1">48.2&#177;15.5</td><td char="." align="char" colspan="1" rowspan="1">0.109</td><td align="left" colspan="1" rowspan="1">47.6&#177;14.9</td><td align="left" colspan="1" rowspan="1">47.4&#177;15.2</td><td align="left" colspan="1" rowspan="1">0.0133</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">1,055 (46.41)</td><td align="left" colspan="1" rowspan="1">1,073 (46.51)</td><td char="." align="char" colspan="1" rowspan="1">0.0019</td><td align="left" colspan="1" rowspan="1">965 (46.41)</td><td align="left" colspan="1" rowspan="1">970 (46.51)</td><td align="left" colspan="1" rowspan="1">0.0048</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">1,214 (53.41)</td><td align="left" colspan="1" rowspan="1">1,230 (53.32)</td><td char="." align="char" colspan="1" rowspan="1">0.0019</td><td align="left" colspan="1" rowspan="1">1,119 (53.41)</td><td align="left" colspan="1" rowspan="1">1,114 (53.32)</td><td align="left" colspan="1" rowspan="1">0.0048</td></tr><tr><td align="left" colspan="1" rowspan="1">Race</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;White</td><td align="left" colspan="1" rowspan="1">1,538 (67.66)</td><td align="left" colspan="1" rowspan="1">1552 (67.27)</td><td char="." align="char" colspan="1" rowspan="1">0.0083</td><td align="left" colspan="1" rowspan="1">1,419 (67.66)</td><td align="left" colspan="1" rowspan="1">1,458 (67.27)</td><td align="left" colspan="1" rowspan="1">0.0404</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Black or African American</td><td align="left" colspan="1" rowspan="1">113 (4.97)</td><td align="left" colspan="1" rowspan="1">159 (6.89)</td><td char="." align="char" colspan="1" rowspan="1">0.0814</td><td align="left" colspan="1" rowspan="1">108 (4.97)</td><td align="left" colspan="1" rowspan="1">98 (6.89)</td><td align="left" colspan="1" rowspan="1">0.0221</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Asian</td><td align="left" colspan="1" rowspan="1">166 (7.30)</td><td align="left" colspan="1" rowspan="1">134 (5.81)</td><td char="." align="char" colspan="1" rowspan="1">0.0604</td><td align="left" colspan="1" rowspan="1">145 (7.30)</td><td align="left" colspan="1" rowspan="1">117 (5.81)</td><td align="left" colspan="1" rowspan="1">0.0553</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown race</td><td align="left" colspan="1" rowspan="1">439 (19.31)</td><td align="left" colspan="1" rowspan="1">454 (19.68)</td><td char="." align="char" colspan="1" rowspan="1">0.0092</td><td align="left" colspan="1" rowspan="1">411 (19.31)</td><td align="left" colspan="1" rowspan="1">410 (19.68)</td><td align="left" colspan="1" rowspan="1">0.0012</td></tr><tr><td align="left" colspan="1" rowspan="1">Comorbidities</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Body mass index</td><td align="left" colspan="1" rowspan="1">325 (14.30)</td><td align="left" colspan="1" rowspan="1">279 (12.09)</td><td char="." align="char" colspan="1" rowspan="1">0.0300</td><td align="left" colspan="1" rowspan="1">281 (14.3)</td><td align="left" colspan="1" rowspan="1">272 (13.26)</td><td align="left" colspan="1" rowspan="1">0.0127</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">238 (10.47)</td><td align="left" colspan="1" rowspan="1">306 (13.26)</td><td char="." align="char" colspan="1" rowspan="1">0.0513</td><td align="left" colspan="1" rowspan="1">225 (10.47)</td><td align="left" colspan="1" rowspan="1">238 (12.09)</td><td align="left" colspan="1" rowspan="1">0.0198</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Gout</td><td align="left" colspan="1" rowspan="1">49 (2.16)</td><td align="left" colspan="1" rowspan="1">56 (2.43)</td><td char="." align="char" colspan="1" rowspan="1">0.0182</td><td align="left" colspan="1" rowspan="1">47 (2.16)</td><td align="left" colspan="1" rowspan="1">45 (2.43)</td><td align="left" colspan="1" rowspan="1">0.0065</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Socioeconomic</td><td align="left" colspan="1" rowspan="1">29 (1.28)</td><td align="left" colspan="1" rowspan="1">27 (1.17)</td><td char="." align="char" colspan="1" rowspan="1">0.0096</td><td align="left" colspan="1" rowspan="1">22 (1.28)</td><td align="left" colspan="1" rowspan="1">24 (1.17)</td><td align="left" colspan="1" rowspan="1">0.0092</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Myelofibrosis</td><td align="left" colspan="1" rowspan="1">10 (0.44)</td><td align="left" colspan="1" rowspan="1">10 (0.43)</td><td char="." align="char" colspan="1" rowspan="1">0.0940</td><td align="left" colspan="1" rowspan="1">10 (0.44)</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="left" colspan="1" rowspan="1">0.0981</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Smoking behavior</td><td align="left" colspan="1" rowspan="1">10 (0.44)</td><td align="left" colspan="1" rowspan="1">10 (0.43)</td><td char="." align="char" colspan="1" rowspan="1">0.0010</td><td align="left" colspan="1" rowspan="1">10 (0.44)</td><td align="left" colspan="1" rowspan="1">10 (0.43)</td><td align="left" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hyperuricemia</td><td align="left" colspan="1" rowspan="1">10 (0.44)</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td char="." align="char" colspan="1" rowspan="1">0.0010</td><td align="left" colspan="1" rowspan="1">10 (0.44)</td><td align="left" colspan="1" rowspan="1">10 (0.43)</td><td align="left" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Lipid</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td char="." align="char" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Medications</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;NSAIDs</td><td align="left" colspan="1" rowspan="1">355 (15.62)</td><td align="left" colspan="1" rowspan="1">290 (12.57)</td><td char="." align="char" colspan="1" rowspan="1">0.0877</td><td align="left" colspan="1" rowspan="1">324 (15.62)</td><td align="left" colspan="1" rowspan="1">257 (12.57)</td><td align="left" colspan="1" rowspan="1">0.0928</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IL23is</italic> IL-23 inhibitors, <italic toggle="yes">IL17is</italic> IL-17 inhibitors, <italic toggle="yes">SD</italic> standardized differences, <italic toggle="yes">NSAIDs</italic> nonsteroidal anti-inflammatory drugs</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>The Risk of Developing Psoriatic Arthritis (PsA) in the IL-23 Inhibitor (IL23i) Cohort Compared to the IL-17 Inhibitor (IL17i) Cohort</title><p id="Par16">The IL23i cohort consisted of 2,273 patients, while the IL17i cohort included 2,307 patients, all identified on or before 31 July 2022. We matched propensity scores to align the two cohorts based on age, sex, race, BMI, smoking behavior, and socioeconomic status (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Using the Cox regression hazards model (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), we assessed the risk of developing PsA in the IL23i cohort compared to the IL17i cohort, yielding a hazard ratio (HR) of 0.60 (95% confidence interval [CI] = 0.44&#8211;0.82, <italic toggle="yes">P</italic> = 0.001). In subgroup analyses, we further investigated the risk of PsA incidence within specific age groups: 18&#8211;40 years, 41&#8211;65 years, and over 65 years, as well as within sex and race groups.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flow chart of the study design</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40259_2025_705_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Forest plot showing the hazard ratios (HRs) and 95% confidence intervals (CIs) associated with variables considered in the univariable analyses with time to the primary endpoint (psoriatic arthritis) as the dependent variable. Blocks represent HRs and horizontal bars extend from the lower limit to the upper limit of the 95% CI of the estimate of the HR. <italic toggle="yes">IL23is</italic> IL-23 inhibitors, <italic toggle="yes">IL17is</italic> IL-17 inhibitors</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40259_2025_705_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Subgroup Analysis by Age and Sex</title><p id="Par17">While more comprehensive 95% CI ranges were observed due to smaller sample sizes, HRs for PsA incidence remained consistently lower than 1 across various age groups and sex categories (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). For individuals aged 18&#8211;40 years, the HR was 0.87 (95% CI 0.44&#8211;1.70, <italic toggle="yes">P</italic> = 0.677). For the age group 41&#8211;65 years, a significant reduction in risk was observed with a HR of 0.42 (95% CI 0.27&#8211;0.64, <italic toggle="yes">P</italic> &lt; 0.001). For patients over 65 years, the HR was 0.86 (95% CI 0.46&#8211;1.60, <italic toggle="yes">P</italic> = 0.622). In subgroup analysis by sex, females had an HR of 0.57 (95% CI 0.38&#8211;0.86, <italic toggle="yes">P</italic> = 0.007) while males had an HR of 0.62 (95% CI 0.37&#8211;1.02, <italic toggle="yes">P</italic> = 0.06).</p></sec><sec id="Sec10"><title>Subgroup Analysis by Ethnic Group</title><p id="Par18">We further performed subgroup analysis by dividing racial groups into White, Black or African American, and Asian (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). White patients had an HR of 0.55 (95% CI 0.38&#8211;0.79, <italic toggle="yes">P</italic> = 0.001), and Black or African American patients had an HR of 1.37 (95% CI 0.37&#8211;5.13, <italic toggle="yes">P</italic> = 0.637). Asian patients had an HR of 0.37 (95% CI 0.10&#8211;1.39, <italic toggle="yes">P</italic> = 0.125).</p></sec><sec id="Sec11"><title>Kaplan-Meier Estimates of Cumulative PsA Incidence for the IL23i and IL17i Cohorts</title><p id="Par19">Kaplan-Meier method estimates of cumulative PsA incidence for the IL23i and IL17i cohorts (Fig. <xref rid="Fig3" ref-type="fig">3</xref>) show that the increase in the cumulative incidence of PsA in the IL17i cohort was significantly higher than in the IL23i cohort (<italic toggle="yes">P</italic> = 0.001). The overall incidence of PsA in the IL17i cohort was 6.0% while that in the IL23i cohort was 5.8% after a 5-year follow-up. A significant reduction in risk was observed in PsO patients aged 41&#8211;65 years, and this finding is consistent with a previous report that the mean age of PsA onset was about 40 years [<xref ref-type="bibr" rid="CR33">33</xref>].<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Cumulative incidence of psoriatic arthritis (PsA) between the IL17i and IL23i cohorts. The increase in the cumulative incidence of PsA in the IL23i cohort was significantly lower than in the IL17i cohort by Kaplan-Meier method estimates (<italic toggle="yes">P</italic> = 0.001). <italic toggle="yes">IL17is</italic> IL-17 inhibitors, <italic toggle="yes">IL23is</italic> IL-23 inhibitors</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="40259_2025_705_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec12"><title>Sensitivity Analysis</title><p id="Par20">To ensure the robustness of the results, this study introduced a control group using TNFis medications. IL23is (risankizumab, guselkumab) and TNFis (etanercept, adalimumab, golimumab, infliximab) were defined as being used within 3 months of a PsO diagnosis, while excluding those with the concurrent use of other medications. PsA was defined as occurring at least 3 months after the PsO diagnosis. Sensitivity analysis showed that the HR of PsA exposed to IL23is compared to TNFis was 0.54 (0.37&#8211;0.77) (Table <xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Risk of psoriatic arthritis after treatment with IL23is compared to TNFis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="3" rowspan="1">No. of event /N</th></tr><tr><th align="left" colspan="1" rowspan="1">IL23is</th><th align="left" colspan="1" rowspan="1">TNFis</th><th align="left" colspan="1" rowspan="1">HR (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Psoriatic arthritis</td><td align="left" colspan="1" rowspan="1">46/778</td><td align="left" colspan="1" rowspan="1">93/778</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.54 (0.37&#8211;0.77)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">TNFis</italic> TNF inhibitors, <italic toggle="yes">IL23is</italic> IL-23 inhibitors</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par21">The results of the present study, which used the TriNetX US Collaborative Network database, highlight the differences between IL23is and IL17is in the risk of incident PsA among patients with PsO. The lower incidence of PsA in patients treated with IL23is, as observed in our study, highlights the central role of IL23 in the pathogenesis of psoriatic diseases [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Although a recent study that investigated TNFis, IL12/23is, IL17is, and IL23is in patients with PsO showed that treatment with IL12/23is or IL23is was associated with a reduced risk of progression to inflammatory arthritis compared with TNFis [<xref ref-type="bibr" rid="CR29">29</xref>]. Our present study demonstrated further evidence regarding direct comparisons between IL23is and IL17is, both of which are more commonly used for patients with PsO, thus providing further guidance in clinical practice [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par22">Animal studies have revealed that excessive IL23 produced from keratinocytes in the skin of mice eventually results in PsO occurrence and is followed by PsA [<xref ref-type="bibr" rid="CR37">37</xref>]. With increased evidence of favorable results with IL23i treating PsO and PsA, McGonagle et al. proposed the treat-to-intercept concept that more aggressive and early treatment of PsO patients could mitigate the risk of PsA occurrence [<xref ref-type="bibr" rid="CR38">38</xref>]. Our study results and current evidence again strongly suggest the pivotal role of IL23 in the pathogenesis of PsA [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par23">Some IL17is inhibit IL17A but not IL17F (e.g., secukinumab, ixekizumab). As IL17F also plays a role in the inflammation of PsA, IL17is that block both IL17A and IL17F may have a higher efficacy in preventing PsA in patients with PsO [<xref ref-type="bibr" rid="CR40">40</xref>]. Additionally, recent research studies have identified that IL23 stabilizes regulatory T cells (Treg) in the tumor microenvironment [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. It could be hypothesized that patients with PsO treated with IL23is have more functional Treg cells that alleviate PsA inflammation and therefore have a lower incidence of PsA. Additionally, the IL23i guselkumab inhibits CD64-CD163- mononuclear phagocytes, preventing subsequent psoriatic inflammation [<xref ref-type="bibr" rid="CR43">43</xref>]. Furthermore, guselkumab reduces memory T cells while maintaining Treg cells, and these effects were not observed with the IL17i secukinumab [<xref ref-type="bibr" rid="CR43">43</xref>]. As tissue-resident memory T cells derived from the skin contribute to the development of PsA [<xref ref-type="bibr" rid="CR44">44</xref>], it could further explain when IL23is may prevent the development of PsA in PsO patients.</p><p id="Par24">Furthermore, the heterogeneity in patient responses to IL17is, as indicated in our results, aligns with the findings of previous studies [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Several studies have suggested that the immune milieu of immune diseases may differ between ethnic groups [<xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>]. This variability underscores the need to evaluate the effectiveness of biological agents in different ethnic groups and regions since different ethnic groups may have different extents of risk factors and comorbidities [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#8211;<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par25">While informative, our study's reliance on retrospective data does have some limitations. First, retrospective studies are prone to biases such as selection bias and recall bias. For example, patients with subclinical PsA may be treated with IL17is rather than IL23is [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Additionally, the literature indicates that different classes of biologics reduce the likelihood of developing peripheral and axial PsA to varying degrees [<xref ref-type="bibr" rid="CR58">58</xref>]. Therefore, while our findings are promising, they should be validated through prospective studies and should evaluate the development of peripheral PsA and axial PsA. Second, although the present study observed differences in efficacy in preventing PsA among ethnic groups using the subset of the TriNetX US Collaborative Network, further investigations conducted in more countries and ethnic groups are warranted to verify the differences. Third, the mean follow-up time was not available from the TriNetX US Collaborative Network, which may limit the ability to fully assess the long-term effectiveness and safety of the treatments. This lack of follow-up data also makes it difficult to evaluate the timing of PsA onset in relation to biologic initiation and may introduce bias in determining the true duration of risk exposure. Last, it is worth further analyzing individual biologic agents within the same class, as biologic agents classified in the same class may have distinct efficacies in preventing PsA.</p><p id="Par26">As suggested by our study, the potential of IL23is to alter the course of PsO and to prevent the development of PsA calls for the re-evaluation of current therapeutic approaches. While current international guidelines for PsO and PsA focus on effectiveness in skin and joint involvement of PsO, future guidelines for psoriatic diseases should tailor personalized treatment strategies in managing PsO and PsA and their comorbidities and potential adverse effects [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. While previous research has indicated that female PsO patients may have an elevated PsA risk [<xref ref-type="bibr" rid="CR50">50</xref>], the present study showed that both male and female PsO patients in the IL23i cohort had a lower incidence of PsA than the IL17i cohort.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par27">Our present study shows that IL23is are more effective than IL17is in preventing PsA in PsO patients. The HR for developing PsA was significantly lower in the IL23i group (HR = 0.60), especially in the 41- to 65-year age group and among females. Subgroup analysis by ethnic groups showed White patients and Asian patients both had lower HRs in contrast to Black or African American patients who had a higher HR. The findings support using IL23is over IL17is for PsO patients at a high risk of PsA, suggesting potential updates to treatment guidelines and emphasizing personalized treatment plans. These results underscore the importance of considering individual patient profiles in therapeutic decision-making. Future research should unravel the molecular mechanisms that underly the differential responses to these inhibitors and the possible unequal efficacy in different ethnic groups and regions that may be caused by different genetic backgrounds or environmental factors [<xref ref-type="bibr" rid="CR54">54</xref>] that should pave the way for more targeted and effective therapies in the management of psoriatic disease.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40259_2025_705_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 33 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p>Sebastian Yu and An-Ping Huo have contributed equally.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This research was funded by grants from the Taiwan National Science and Technology Council (NSTC-111-2314-B-037-042, NSTC-112-2221-E-020-005, and NSTC-113-2314-B-037-076-MY3) to S.Y. The authors wish to express their sincere gratitude to Dr. Chang-Bi Wang for his invaluable assistance with the statistical analyses. This article utilized ChatGPT by OpenAI to refine the English language.</p></ack><notes><title>Declarations</title><notes notes-type="funding"><title>Funding information</title><p id="Par28">This research was funded by a grant from the Taiwan National Science and Technology Council (NSTC-111-2314-B-037-042, NSTC-112-2221-E-020-005, and NSTC-113-2314-B-037-076-MY3) to S.Y.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Conflicts of Interest Statement</title><p id="Par29">None declared.</p></notes><notes><title>Research Ethics Approval, Human Participants</title><p id="Par30">TriNetX obtained a waiver from the Western Institutional Review Board (WIRB) due to its provision of aggregated counts and statistical summaries of de-identified data, adhering to the de-identification standards specified in Section &#167;164.514(a) of the HIPAA Privacy Rule. This study was approved by Chung Shan Medical University Hospital Institutional Review Board (IRB NO: CS2-21176).</p></notes><notes id="FPar2"><title>Data availability Statement</title><p id="Par31">The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Patient and Public Involvement Statement</title><p id="Par32">Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.</p></notes><notes notes-type="author-contribution"><title>Author Contributions</title><p id="Par33"><italic toggle="yes">Conceptualization:</italic> Sebastian Yu, An-Ping Huo, James Cheng-Chung Wei. <italic toggle="yes">Methodology:</italic> Sebastian Yu, Yu-Hsun Wang, James Cheng-Chung Wei. <italic toggle="yes">Formal analysis and investigation:</italic> Sebastian Yu, Yu-Hsun Wang, James Cheng-Chung Wei. <italic toggle="yes">Writing</italic> &#8211; <italic toggle="yes">original draft preparation:</italic> Sebastian Yu, An-Ping Huo. <italic toggle="yes">Writing - review and editing:</italic> Yu-Hsun Wang, James Cheng-Chung Wei. <italic toggle="yes">Funding acquisition:</italic> Sebastian Yu, James Cheng-Chung Wei. <italic toggle="yes">Resources:</italic> James Cheng-Chung Wei. <italic toggle="yes">Supervision:</italic> James Cheng-Chung Wei.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>MM</given-names></name><name name-style="western"><surname>Moseley</surname><given-names>IH</given-names></name><name name-style="western"><surname>George</surname><given-names>EA</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Cho</surname><given-names>E</given-names></name></person-group><article-title>Examining the burden of psoriasis and psoriatic arthritis in a US adult cohort using the All of Us Research Program</article-title><source>J Am Acad Dermatol</source><year>2023</year><volume>89</volume><issue>4</issue><fpage>859</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2023.06.028</pub-id><pub-id pub-id-type="pmid">37356625</pub-id><pub-id pub-id-type="pmcid">PMC11187795</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Tran MM, Moseley IH, George EA, Qureshi AA, Cho E. Examining the burden of psoriasis and psoriatic arthritis in a US adult cohort using the All of Us Research Program. J Am Acad Dermatol. 2023;89(4):859&#8211;62.<pub-id pub-id-type="pmid">37356625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2023.06.028</pub-id><pub-id pub-id-type="pmcid">PMC11187795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis</article-title><source>Bmc Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>421</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02617-5</pub-id><pub-id pub-id-type="pmid">36320003</pub-id><pub-id pub-id-type="pmcid">PMC9628092</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. Bmc Med. 2022;20(1):421.<pub-id pub-id-type="pmid">36320003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-022-02617-5</pub-id><pub-id pub-id-type="pmcid">PMC9628092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piaserico</surname><given-names>S</given-names></name><name name-style="western"><surname>Orlando</surname><given-names>G</given-names></name><name name-style="western"><surname>Messina</surname><given-names>F</given-names></name></person-group><article-title>Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>16</issue><fpage>9063</fpage><pub-id pub-id-type="doi">10.3390/ijms23169063</pub-id><pub-id pub-id-type="pmid">36012327</pub-id><pub-id pub-id-type="pmcid">PMC9409274</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Piaserico S, Orlando G, Messina F. Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways. Int J Mol Sci. 2022;23(16):9063.<pub-id pub-id-type="pmid">36012327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23169063</pub-id><pub-id pub-id-type="pmcid">PMC9409274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kavanaugh</surname><given-names>A</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>MG</given-names></name><name name-style="western"><surname>Gniadecki</surname><given-names>R</given-names></name><name name-style="western"><surname>Merola</surname><given-names>JF</given-names></name></person-group><article-title>Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis</article-title><source>J Eur Acad Dermatol Venereol</source><year>2022</year><volume>36</volume><issue>6</issue><fpage>797</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1111/jdv.18044</pub-id><pub-id pub-id-type="pmid">35238067</pub-id><pub-id pub-id-type="pmcid">PMC9313585</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797&#8211;806.<pub-id pub-id-type="pmid">35238067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.18044</pub-id><pub-id pub-id-type="pmcid">PMC9313585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S-F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T-H</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P-E</given-names></name><name name-style="western"><surname>Chi</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Tung</surname><given-names>T-H</given-names></name></person-group><article-title>Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: a systematic review and meta-analysis of cohort studies</article-title><source>Dermatol Sin</source><year>2021</year><volume>39</volume><issue>1</issue><fpage>19</fpage><pub-id pub-id-type="doi">10.4103/ds.ds_55_20</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Yang S-F, Chen T-H, Tsai S-H, Chen P-E, Chi C-C, Tung T-H. Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: a systematic review and meta-analysis of cohort studies. Dermatol Sin. 2021;39(1):19.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungprasert</surname><given-names>P</given-names></name><name name-style="western"><surname>Raksasuk</surname><given-names>S</given-names></name></person-group><article-title>Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis</article-title><source>Int Urol Nephrol</source><year>2018</year><volume>50</volume><issue>7</issue><fpage>1277</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1007/s11255-018-1868-z</pub-id><pub-id pub-id-type="pmid">29644523</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277&#8211;83.<pub-id pub-id-type="pmid">29644523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11255-018-1868-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>M</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of psoriasis with depression, anxiety, and suicidality: a bidirectional two-sample Mendelian randomization study</article-title><source>J Dermatol</source><year>2023</year><volume>50</volume><issue>12</issue><fpage>1629</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.16941</pub-id><pub-id pub-id-type="pmid">37697936</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chu M, Shen S, Zhu Z, Li Z, Bai Y, Ma J, et al. Association of psoriasis with depression, anxiety, and suicidality: a bidirectional two-sample Mendelian randomization study. J Dermatol. 2023;50(12):1629&#8211;34.<pub-id pub-id-type="pmid">37697936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1346-8138.16941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>CL</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Tu</surname><given-names>HP</given-names></name><name name-style="western"><surname>Lan</surname><given-names>CE</given-names></name></person-group><article-title>Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2017</year><volume>31</volume><issue>9</issue><fpage>1497</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1111/jdv.14303</pub-id><pub-id pub-id-type="pmid">28467611</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Yu S, Yu CL, Huang YC, Tu HP, Lan CE. Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2017;31(9):1497&#8211;504.<pub-id pub-id-type="pmid">28467611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.14303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>H-P</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C-L</given-names></name><name name-style="western"><surname>Lan</surname><given-names>C-CE</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of schizophrenia in patients with psoriasis: a nationwide study</article-title><source>Dermatol Sin</source><year>2017</year><volume>35</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.dsi.2016.07.005</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Tu H-P, Yu C-L, Lan C-CE, Yu S. Prevalence of schizophrenia in patients with psoriasis: a nationwide study. Dermatol Sin. 2017;35(1):1&#8211;6.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AlQassimi</surname><given-names>S</given-names></name><name name-style="western"><surname>AlBrashdi</surname><given-names>S</given-names></name><name name-style="western"><surname>Galadari</surname><given-names>H</given-names></name><name name-style="western"><surname>Hashim</surname><given-names>MJ</given-names></name></person-group><article-title>Global burden of psoriasis&#8211;comparison of regional and global epidemiology, 1990 to 2017</article-title><source>Int J Dermatol</source><year>2020</year><volume>59</volume><issue>5</issue><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1111/ijd.14864</pub-id><pub-id pub-id-type="pmid">32250451</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis&#8211;comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566&#8211;71.<pub-id pub-id-type="pmid">32250451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijd.14864</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Suryavanshi</surname><given-names>M</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>D</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name><name name-style="western"><surname>Seigel</surname><given-names>L</given-names></name></person-group><article-title>Economic burden of comorbidities in patients with psoriasis in the USA</article-title><source>Dermatol Ther (Heidelb).</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1007/s13555-022-00832-9</pub-id><pub-id pub-id-type="pmid">36402940</pub-id><pub-id pub-id-type="pmcid">PMC9823180</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Economic burden of comorbidities in patients with psoriasis in the USA. Dermatol Ther (Heidelb). 2023;13(1):207&#8211;19.<pub-id pub-id-type="pmid">36402940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13555-022-00832-9</pub-id><pub-id pub-id-type="pmcid">PMC9823180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>HT</given-names></name><name name-style="western"><surname>Vu</surname><given-names>AT</given-names></name><name name-style="western"><surname>Pham</surname><given-names>NTU</given-names></name><name name-style="western"><surname>Tran</surname><given-names>TNA</given-names></name><name name-style="western"><surname>Pham</surname><given-names>NN</given-names></name><name name-style="western"><surname>Bui</surname><given-names>HTT</given-names></name><etal/></person-group><article-title>Comorbidity burden and treatment patterns of psoriasis in vietnam: real-world data from the EXPAND Study</article-title><source>Dermatol Ther (Heidelb).</source><year>2023</year><volume>13</volume><issue>12</issue><fpage>3193</fpage><lpage>3208</lpage><pub-id pub-id-type="doi">10.1007/s13555-023-01062-3</pub-id><pub-id pub-id-type="pmid">37978119</pub-id><pub-id pub-id-type="pmcid">PMC10689324</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Nguyen HT, Vu AT, Pham NTU, Tran TNA, Pham NN, Bui HTT, et al. Comorbidity burden and treatment patterns of psoriasis in vietnam: real-world data from the EXPAND Study. Dermatol Ther (Heidelb). 2023;13(12):3193&#8211;208.<pub-id pub-id-type="pmid">37978119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13555-023-01062-3</pub-id><pub-id pub-id-type="pmcid">PMC10689324</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Tran</surname><given-names>MH</given-names></name></person-group><article-title>Economic and comorbidity burden among patients with moderate-to-severe psoriasis</article-title><source>J Manag Care Spec Pharm</source><year>2015</year><volume>21</volume><issue>10</issue><fpage>874</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">26402388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2015.21.10.874</pub-id><pub-id pub-id-type="pmcid">PMC10397856</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874&#8211;88.<pub-id pub-id-type="pmid">26402388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2015.21.10.874</pub-id><pub-id pub-id-type="pmcid">PMC10397856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Tran</surname><given-names>MH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name></person-group><article-title>Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis</article-title><source>Arthritis Care Res (Hoboken).</source><year>2015</year><volume>67</volume><issue>5</issue><fpage>708</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1002/acr.22492</pub-id><pub-id pub-id-type="pmid">25303478</pub-id><pub-id pub-id-type="pmcid">PMC5029589</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67(5):708&#8211;17.<pub-id pub-id-type="pmid">25303478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.22492</pub-id><pub-id pub-id-type="pmcid">PMC5029589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wei</surname><given-names>JC</given-names></name></person-group><article-title>Regarding Mastorino et al.&#8217;s 'Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients'</article-title><source>J Eur Acad Dermatol Venereol</source><year>2023</year><volume>37</volume><issue>12</issue><fpage>e1388</fpage><lpage>e1389</lpage><pub-id pub-id-type="doi">10.1111/jdv.19334</pub-id><pub-id pub-id-type="pmid">37458245</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Yu S, Wei JC. Regarding Mastorino et al.&#8217;s &#8220;Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.&#8221; J Eur Acad Dermatol Venereol. 2023;37(12):e1388&#8211;9.<pub-id pub-id-type="pmid">37458245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.19334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blauvelt</surname><given-names>A</given-names></name><name name-style="western"><surname>Pariser</surname><given-names>DM</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagel</surname><given-names>J</given-names></name><name name-style="western"><surname>Alexis</surname><given-names>AF</given-names></name><name name-style="western"><surname>Soung</surname><given-names>J</given-names></name><etal/></person-group><article-title>Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study</article-title><source>J Dermatol Sci</source><year>2023</year><volume>109</volume><issue>1</issue><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2023.01.003</pub-id><pub-id pub-id-type="pmid">36690571</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, et al. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J Dermatol Sci. 2023;109(1):12&#8211;21.<pub-id pub-id-type="pmid">36690571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdermsci.2023.01.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacharanukrauh</surname><given-names>P</given-names></name><name name-style="western"><surname>Meephansan</surname><given-names>J</given-names></name><name name-style="western"><surname>Ponnikorn</surname><given-names>S</given-names></name><name name-style="western"><surname>Tangtanatakul</surname><given-names>P</given-names></name><name name-style="western"><surname>Soonthornchai</surname><given-names>W</given-names></name><name name-style="western"><surname>Wongpiyabovorn</surname><given-names>J</given-names></name><etal/></person-group><article-title>Transcriptome profiling in psoriasis: NB-UVB treatment-associated transcriptional changes and modulation of autoinflammation in perilesional skin in early-phase disease</article-title><source>J Dermatol Sci</source><year>2022</year><volume>107</volume><issue>3</issue><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2022.08.004</pub-id><pub-id pub-id-type="pmid">35995712</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Vacharanukrauh P, Meephansan J, Ponnikorn S, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, et al. Transcriptome profiling in psoriasis: NB-UVB treatment-associated transcriptional changes and modulation of autoinflammation in perilesional skin in early-phase disease. J Dermatol Sci. 2022;107(3):123&#8211;32.<pub-id pub-id-type="pmid">35995712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdermsci.2022.08.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azuaga</surname><given-names>AB</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>J</given-names></name><name name-style="western"><surname>Canete</surname><given-names>JD</given-names></name></person-group><article-title>Psoriatic arthritis: pathogenesis and targeted therapies</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>5</issue><fpage>4901</fpage><pub-id pub-id-type="doi">10.3390/ijms24054901</pub-id><pub-id pub-id-type="pmid">36902329</pub-id><pub-id pub-id-type="pmcid">PMC10003101</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Azuaga AB, Ramirez J, Canete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901.<pub-id pub-id-type="pmid">36902329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24054901</pub-id><pub-id pub-id-type="pmcid">PMC10003101</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>AW</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Flavin</surname><given-names>S</given-names></name><name name-style="western"><surname>Randazzo</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10201</issue><fpage>831</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31773-8</pub-id><pub-id pub-id-type="pmid">31402114</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831&#8211;9.<pub-id pub-id-type="pmid">31402114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)31773-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mastorino</surname><given-names>L</given-names></name><name name-style="western"><surname>Susca</surname><given-names>S</given-names></name><name name-style="western"><surname>Cariti</surname><given-names>C</given-names></name><name name-style="western"><surname>Sliquini</surname><given-names>N</given-names></name><name name-style="western"><surname>Verrone</surname><given-names>A</given-names></name><name name-style="western"><surname>Stroppiana</surname><given-names>E</given-names></name><etal/></person-group><article-title>Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients</article-title><source>J Eur Acad Dermatol Venereol</source><year>2023</year><volume>37</volume><issue>9</issue><fpage>1848</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.1111/jdv.19135</pub-id><pub-id pub-id-type="pmid">37113043</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E, et al. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. J Eur Acad Dermatol Venereol. 2023;37(9):1848&#8211;53.<pub-id pub-id-type="pmid">37113043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.19135</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gisondi</surname><given-names>P</given-names></name><name name-style="western"><surname>Bellinato</surname><given-names>F</given-names></name><name name-style="western"><surname>Targher</surname><given-names>G</given-names></name><name name-style="western"><surname>Idolazzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Girolomoni</surname><given-names>G</given-names></name></person-group><article-title>Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis</article-title><source>Ann Rheum Dis</source><year>2022</year><volume>81</volume><issue>1</issue><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2021-219961</pub-id><pub-id pub-id-type="pmid">34144965</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68&#8211;73.<pub-id pub-id-type="pmid">34144965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2021-219961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watad</surname><given-names>A</given-names></name><name name-style="western"><surname>Zabotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Patt</surname><given-names>YS</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>O</given-names></name><name name-style="western"><surname>Dotan</surname><given-names>A</given-names></name><name name-style="western"><surname>Ben-Shabat</surname><given-names>N</given-names></name><etal/></person-group><article-title>From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis</article-title><source>Rheumatol Ther.</source><year>2024</year><volume>11</volume><issue>4</issue><fpage>963</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1007/s40744-024-00680-3</pub-id><pub-id pub-id-type="pmid">38847993</pub-id><pub-id pub-id-type="pmcid">PMC11264659</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Watad A, Zabotti A, Patt YS, Gendelman O, Dotan A, Ben-Shabat N, et al. From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11(4):963&#8211;76.<pub-id pub-id-type="pmid">38847993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40744-024-00680-3</pub-id><pub-id pub-id-type="pmcid">PMC11264659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabotti</surname><given-names>A</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>G</given-names></name><name name-style="western"><surname>Gossec</surname><given-names>L</given-names></name><name name-style="western"><surname>Baraliakos</surname><given-names>X</given-names></name><name name-style="western"><surname>Aletaha</surname><given-names>D</given-names></name><name name-style="western"><surname>Iagnocco</surname><given-names>A</given-names></name><etal/></person-group><article-title>EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis</article-title><source>Ann Rheum Dis</source><year>2023</year><volume>82</volume><issue>9</issue><fpage>1162</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1136/ard-2023-224148</pub-id><pub-id pub-id-type="pmid">37295926</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162&#8211;70.<pub-id pub-id-type="pmid">37295926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard-2023-224148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Marco</surname><given-names>G</given-names></name><name name-style="western"><surname>Zabotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Baraliakos</surname><given-names>X</given-names></name><name name-style="western"><surname>Iagnocco</surname><given-names>A</given-names></name><name name-style="western"><surname>Aletaha</surname><given-names>D</given-names></name><name name-style="western"><surname>Gisondi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce</article-title><source>RMD Open</source><year>2023</year><volume>9</volume><issue>2</issue><fpage>e003143</fpage><pub-id pub-id-type="doi">10.1136/rmdopen-2023-003143</pub-id><pub-id pub-id-type="pmid">37349122</pub-id><pub-id pub-id-type="pmcid">PMC10314670</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">De Marco G, Zabotti A, Baraliakos X, Iagnocco A, Aletaha D, Gisondi P, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open. 2023;9(2): e003143.<pub-id pub-id-type="pmid">37349122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/rmdopen-2023-003143</pub-id><pub-id pub-id-type="pmcid">PMC10314670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Shentu</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials</article-title><source>Immunol Res</source><year>2023</year><volume>71</volume><issue>4</issue><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1007/s12026-023-09366-4</pub-id><pub-id pub-id-type="pmid">36811818</pub-id><pub-id pub-id-type="pmcid">PMC10425519</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023;71(4):505&#8211;15.<pub-id pub-id-type="pmid">36811818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-023-09366-4</pub-id><pub-id pub-id-type="pmcid">PMC10425519</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haberman</surname><given-names>RH</given-names></name><name name-style="western"><surname>MacFarlane</surname><given-names>KA</given-names></name><name name-style="western"><surname>Catron</surname><given-names>S</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>J</given-names></name><name name-style="western"><surname>Blank</surname><given-names>RB</given-names></name><name name-style="western"><surname>Toprover</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><issue>12</issue><fpage>e063650</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-063650</pub-id><pub-id pub-id-type="pmid">36564123</pub-id><pub-id pub-id-type="pmcid">PMC9791418</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12): e063650.<pub-id pub-id-type="pmid">36564123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2022-063650</pub-id><pub-id pub-id-type="pmcid">PMC9791418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ak</surname><given-names>T</given-names></name><name name-style="western"><surname>Temiz</surname><given-names>SNY</given-names></name><name name-style="western"><surname>Taner</surname><given-names>M</given-names></name><name name-style="western"><surname>Ayla</surname><given-names>AY</given-names></name><name name-style="western"><surname>Aygun</surname><given-names>AA</given-names></name><name name-style="western"><surname>Engin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: a pilot prospective real-world study</article-title><source>Int J Rheum Dis</source><year>2023</year><volume>26</volume><issue>5</issue><fpage>878</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14663</pub-id><pub-id pub-id-type="pmid">36929151</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ak T, Temiz SNY, Taner M, Ayla AY, Aygun AA, Engin B, et al. Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: a pilot prospective real-world study. Int J Rheum Dis. 2023;26(5):878&#8211;84.<pub-id pub-id-type="pmid">36929151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1756-185X.14663</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldarola</surname><given-names>G</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>E</given-names></name><name name-style="western"><surname>Bavetta</surname><given-names>M</given-names></name><name name-style="western"><surname>Bernardini</surname><given-names>N</given-names></name><name name-style="western"><surname>Dattola</surname><given-names>A</given-names></name><name name-style="western"><surname>De Simone</surname><given-names>C</given-names></name><etal/></person-group><article-title>2-Year experience with risankizumab in the treatment of plaque psoriasis in Lazio region, Italy</article-title><source>Dermatol Ther</source><year>2023</year><volume>19</volume><fpage>2023</fpage></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Caldarola G, De Luca E, Bavetta M, Bernardini N, Dattola A, De Simone C, et al. 2-Year experience with risankizumab in the treatment of plaque psoriasis in Lazio region, Italy. Dermatol Ther. 2023;19:2023.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singla</surname><given-names>S</given-names></name><name name-style="western"><surname>Putman</surname><given-names>M</given-names></name><name name-style="western"><surname>Liew</surname><given-names>J</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>K</given-names></name></person-group><article-title>Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study</article-title><source>Lancet Rheumatol.</source><year>2023</year><volume>5</volume><issue>4</issue><fpage>e200</fpage><lpage>e207</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(23)00034-6</pub-id><pub-id pub-id-type="pmid">38251522</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200&#8211;7.<pub-id pub-id-type="pmid">38251522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2665-9913(23)00034-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yen</surname><given-names>FS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SI</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wei</surname><given-names>JC</given-names></name></person-group><article-title>Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus</article-title><source>JAMA Netw Open</source><year>2024</year><volume>7</volume><issue>6</issue><fpage>e2416578</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.16578</pub-id><pub-id pub-id-type="pmid">38865122</pub-id><pub-id pub-id-type="pmcid">PMC11170305</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open. 2024;7(6): e2416578.<pub-id pub-id-type="pmid">38865122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.16578</pub-id><pub-id pub-id-type="pmcid">PMC11170305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>TH</given-names></name><name name-style="western"><surname>Ibarburu</surname><given-names>GH</given-names></name><name name-style="western"><surname>Wei</surname><given-names>JCC</given-names></name></person-group><article-title>Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study</article-title><source>Bmc Med</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/s12916-024-03331-0</pub-id><pub-id pub-id-type="pmid">38481216</pub-id><pub-id pub-id-type="pmcid">PMC10938827</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang WJ, Wang YH, Huang CH, Hsieh TH, Ibarburu GH, Wei JCC. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study. Bmc Med. 2024;22(1):117.<pub-id pub-id-type="pmid">38481216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-024-03331-0</pub-id><pub-id pub-id-type="pmcid">PMC10938827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>RY</given-names></name><name name-style="western"><surname>Gau</surname><given-names>SY</given-names></name><name name-style="western"><surname>Ho</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SY</given-names></name><name name-style="western"><surname>Ku</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Long-COVID impacts taste and olfactory in individuals with substance use disorder: a retrospective cohort study from the TriNetX US Collaborative Networks</article-title><source>Psychiatry Res</source><year>2024</year><volume>337</volume><fpage>115970</fpage><pub-id pub-id-type="doi">10.1016/j.psychres.2024.115970</pub-id><pub-id pub-id-type="pmid">38810537</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tsai RY, Gau SY, Ho YJ, Lin SY, Ku CY, Wang SI, et al. Long-COVID impacts taste and olfactory in individuals with substance use disorder: a retrospective cohort study from the TriNetX US Collaborative Networks. Psychiatry Res. 2024;337: 115970.<pub-id pub-id-type="pmid">38810537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2024.115970</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>YP</given-names></name><name name-style="western"><surname>Loo</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lim</surname><given-names>AL</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CK</given-names></name><name name-style="western"><surname>Ali</surname><given-names>NBM</given-names></name><name name-style="western"><surname>Khor</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Prevalence and risk factors associated with psoriatic arthritis among patients with psoriasis</article-title><source>Int J Rheum Dis</source><year>2023</year><volume>26</volume><issue>9</issue><fpage>1788</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14833</pub-id><pub-id pub-id-type="pmid">37485806</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Loo YP, Loo CH, Lim AL, Wong CK, Ali NBM, Khor YH, et al. Prevalence and risk factors associated with psoriatic arthritis among patients with psoriasis. Int J Rheum Dis. 2023;26(9):1788&#8211;98.<pub-id pub-id-type="pmid">37485806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1756-185X.14833</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022 Nov;20 Suppl 1(Suppl 1):S12-S21.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/msc.1694</pub-id><pub-id pub-id-type="pmcid">PMC9825973</pub-id><pub-id pub-id-type="pmid">36069174</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Yu S, Lee CW, Li YA, Chen TH, HS Y. Prenatal infection predisposes offspring to enhanced susceptibility to imiquimod-mediated psoriasiform dermatitis in mice. Dermatol Sin. 2022;40(1):14-9.</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiricozzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Coscarella</surname><given-names>G</given-names></name><name name-style="western"><surname>Puig</surname><given-names>L</given-names></name><name name-style="western"><surname>Vender</surname><given-names>R</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>J</given-names></name><name name-style="western"><surname>Carrascosa</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2024</year><volume>38</volume><issue>11</issue><fpage>2175</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1111/jdv.20143</pub-id><pub-id pub-id-type="pmid">38860729</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, et al. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study. J Eur Acad Dermatol Venereol. 2024;38(11):2175&#8211;85.<pub-id pub-id-type="pmid">38860729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.20143</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>M</given-names></name><name name-style="western"><surname>Grisotto</surname><given-names>M</given-names></name><name name-style="western"><surname>Smaldini</surname><given-names>P</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>8259</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-65269-6</pub-id><pub-id pub-id-type="pmid">32427877</pub-id><pub-id pub-id-type="pmcid">PMC7237669</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Chen L, Deshpande M, Grisotto M, Smaldini P, Garcia R, He Z, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10(1):8259.<pub-id pub-id-type="pmid">32427877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-65269-6</pub-id><pub-id pub-id-type="pmcid">PMC7237669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGonagle</surname><given-names>DG</given-names></name><name name-style="western"><surname>Zabotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Watad</surname><given-names>A</given-names></name><name name-style="western"><surname>Bridgewood</surname><given-names>C</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>G</given-names></name><name name-style="western"><surname>Kerschbaumer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?</article-title><source>Ann Rheum Dis</source><year>2022</year><volume>81</volume><issue>1</issue><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2021-221255</pub-id><pub-id pub-id-type="pmid">34810194</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">McGonagle DG, Zabotti A, Watad A, Bridgewood C, De Marco G, Kerschbaumer A, et al. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? Ann Rheum Dis. 2022;81(1):7&#8211;10.<pub-id pub-id-type="pmid">34810194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2021-221255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>R</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: a systematic review and aggregate data meta-analysis of randomized controlled trials</article-title><source>Int J Rheum Dis</source><year>2023</year><volume>26</volume><issue>4</issue><fpage>625</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14603</pub-id><pub-id pub-id-type="pmid">36760030</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Cai R, Jin Y, Chen B, Zhao J, Zhai J, Zeng L, et al. Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: a systematic review and aggregate data meta-analysis of randomized controlled trials. Int J Rheum Dis. 2023;26(4):625&#8211;37.<pub-id pub-id-type="pmid">36760030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1756-185X.14603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>T</given-names></name><name name-style="western"><surname>Shirley</surname><given-names>M</given-names></name></person-group><article-title>Bimekizumab: a review in psoriatic arthritis</article-title><source>Drugs</source><year>2024</year><volume>84</volume><issue>5</issue><fpage>587</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1007/s40265-024-02026-3</pub-id><pub-id pub-id-type="pmid">38703349</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Nie T, Shirley M. Bimekizumab: a review in psoriatic arthritis. Drugs. 2024;84(5):587&#8211;98.<pub-id pub-id-type="pmid">38703349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-024-02026-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wertheimer</surname><given-names>T</given-names></name><name name-style="western"><surname>Zwicky</surname><given-names>P</given-names></name><name name-style="western"><surname>Rindlisbacher</surname><given-names>L</given-names></name><name name-style="western"><surname>Sparano</surname><given-names>C</given-names></name><name name-style="western"><surname>Vermeer</surname><given-names>M</given-names></name><name name-style="western"><surname>de Melo</surname><given-names>BMS</given-names></name><etal/></person-group><article-title>IL-23 stabilizes an effector T(reg) cell program in the tumor microenvironment</article-title><source>Nat Immunol</source><year>2024</year><volume>25</volume><issue>3</issue><fpage>512</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1038/s41590-024-01755-7</pub-id><pub-id pub-id-type="pmid">38356059</pub-id><pub-id pub-id-type="pmcid">PMC10907296</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Wertheimer T, Zwicky P, Rindlisbacher L, Sparano C, Vermeer M, de Melo BMS, et al. IL-23 stabilizes an effector T(reg) cell program in the tumor microenvironment. Nat Immunol. 2024;25(3):512&#8211;24.<pub-id pub-id-type="pmid">38356059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-024-01755-7</pub-id><pub-id pub-id-type="pmcid">PMC10907296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobse</surname><given-names>J</given-names></name><name name-style="western"><surname>Pilat</surname><given-names>JM</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RE</given-names></name><name name-style="western"><surname>Kwag</surname><given-names>A</given-names></name><name name-style="western"><surname>Buendia</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Distinct roles for interleukin-23 receptor signaling in regulatory T cells in sporadic and inflammation-associated carcinogenesis</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1276743</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1276743</pub-id><pub-id pub-id-type="pmid">38375204</pub-id><pub-id pub-id-type="pmcid">PMC10876294</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Jacobse J, Pilat JM, Li J, Brown RE, Kwag A, Buendia MA, et al. Distinct roles for interleukin-23 receptor signaling in regulatory T cells in sporadic and inflammation-associated carcinogenesis. Front Oncol. 2023;13:1276743.<pub-id pub-id-type="pmid">38375204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1276743</pub-id><pub-id pub-id-type="pmcid">PMC10876294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>H</given-names></name><name name-style="western"><surname>Mashiko</surname><given-names>S</given-names></name><name name-style="western"><surname>Angsana</surname><given-names>J</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>M</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>YM</given-names></name><name name-style="western"><surname>Maari</surname><given-names>C</given-names></name><etal/></person-group><article-title>Differential changes in inflammatory mononuclear phagocyte and t-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab</article-title><source>J Invest Dermatol</source><year>2021</year><volume>141</volume><issue>7</issue><fpage>1707</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2021.01.005</pub-id><pub-id pub-id-type="pmid">33524368</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C, et al. Differential changes in inflammatory mononuclear phagocyte and t-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707&#8211;18.<pub-id pub-id-type="pmid">33524368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2021.01.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leijten</surname><given-names>EF</given-names></name><name name-style="western"><surname>van Kempen</surname><given-names>TS</given-names></name><name name-style="western"><surname>Olde Nordkamp</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pouw</surname><given-names>JN</given-names></name><name name-style="western"><surname>Kleinrensink</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Vincken</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis</article-title><source>Arthritis Rheumatol</source><year>2021</year><volume>73</volume><issue>7</issue><fpage>1220</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1002/art.41652</pub-id><pub-id pub-id-type="pmid">33452865</pub-id><pub-id pub-id-type="pmcid">PMC8362143</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL, et al. Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol. 2021;73(7):1220&#8211;32.<pub-id pub-id-type="pmid">33452865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.41652</pub-id><pub-id pub-id-type="pmcid">PMC8362143</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>T</given-names></name><name name-style="western"><surname>Puig</surname><given-names>L</given-names></name><name name-style="western"><surname>Vender</surname><given-names>R</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>J</given-names></name><name name-style="western"><surname>Carrascosa</surname><given-names>JM</given-names></name><name name-style="western"><surname>Piaserico</surname><given-names>S</given-names></name><etal/></person-group><article-title>Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study</article-title><source>Am J Clin Dermatol</source><year>2022</year><volume>23</volume><issue>6</issue><fpage>891</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1007/s40257-022-00722-y</pub-id><pub-id pub-id-type="pmid">35976568</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891&#8211;904.<pub-id pub-id-type="pmid">35976568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40257-022-00722-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiricozzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Maurelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>L</given-names></name><name name-style="western"><surname>Peris</surname><given-names>K</given-names></name><name name-style="western"><surname>Girolomoni</surname><given-names>G</given-names></name></person-group><article-title>Overview of atopic dermatitis in different ethnic groups</article-title><source>J Clin Med</source><year>2023</year><volume>12</volume><issue>7</issue><fpage>2701</fpage><pub-id pub-id-type="doi">10.3390/jcm12072701</pub-id><pub-id pub-id-type="pmid">37048783</pub-id><pub-id pub-id-type="pmcid">PMC10095524</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Chiricozzi A, Maurelli M, Calabrese L, Peris K, Girolomoni G. Overview of atopic dermatitis in different ethnic groups. J Clin Med. 2023;12(7):2701.<pub-id pub-id-type="pmid">37048783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12072701</pub-id><pub-id pub-id-type="pmcid">PMC10095524</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>SF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>MH</given-names></name><name name-style="western"><surname>Chou</surname><given-names>PC</given-names></name><name name-style="western"><surname>Hu</surname><given-names>SK</given-names></name><name name-style="western"><surname>Shih</surname><given-names>SY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics</article-title><source>Genes (Basel).</source><year>2023</year><volume>14</volume><issue>6</issue><fpage>1297</fpage><pub-id pub-id-type="doi">10.3390/genes14061297</pub-id><pub-id pub-id-type="pmid">37372477</pub-id><pub-id pub-id-type="pmcid">PMC10297910</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Yang SF, Lin MH, Chou PC, Hu SK, Shih SY, Yu HS, et al. Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics. Genes (Basel). 2023;14(6):1297.<pub-id pub-id-type="pmid">37372477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes14061297</pub-id><pub-id pub-id-type="pmcid">PMC10297910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Yu S, Tsao YH, Tu HP, CCE L. Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan. Dermatol Sin. 2022;40(1):20-7.</mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mastorino</surname><given-names>L</given-names></name><name name-style="western"><surname>Ortoncelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Dapavo</surname><given-names>P</given-names></name><name name-style="western"><surname>Ribero</surname><given-names>S</given-names></name><name name-style="western"><surname>Quaglino</surname><given-names>P</given-names></name></person-group><article-title>Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients'-response to Yu et al</article-title><source>J Eur Acad Dermatol Venereol</source><year>2024</year><volume>38</volume><issue>2</issue><fpage>e175</fpage><lpage>e176</lpage><pub-id pub-id-type="doi">10.1111/jdv.19517</pub-id><pub-id pub-id-type="pmid">37708568</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Mastorino L, Ortoncelli M, Dapavo P, Ribero S, Quaglino P. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients&#8217;-response to Yu et al. J Eur Acad Dermatol Venereol. 2024;38(2):e175&#8211;6.<pub-id pub-id-type="pmid">37708568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.19517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershater</surname><given-names>B</given-names></name><name name-style="western"><surname>Bieber</surname><given-names>K</given-names></name><name name-style="western"><surname>Vorobyev</surname><given-names>A</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zirpel</surname><given-names>H</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: a sex- and ethnicity-specific analysis</article-title><source>Front Med (Lausanne).</source><year>2024</year><volume>11</volume><fpage>1385491</fpage><pub-id pub-id-type="doi">10.3389/fmed.2024.1385491</pub-id><pub-id pub-id-type="pmid">38975056</pub-id><pub-id pub-id-type="pmcid">PMC11224429</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Gershater B, Bieber K, Vorobyev A, Ludwig MA, Zirpel H, De Luca DA, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: a sex- and ethnicity-specific analysis. Front Med (Lausanne). 2024;11:1385491.<pub-id pub-id-type="pmid">38975056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1385491</pub-id><pub-id pub-id-type="pmcid">PMC11224429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dou</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis</article-title><source>Int J Rheum Dis</source><year>2023</year><volume>26</volume><issue>9</issue><fpage>1737</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14805</pub-id><pub-id pub-id-type="pmid">37424174</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Lu C, Yang F, Liu H, Dou L, Wang Y, Li H, et al. Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1737&#8211;44.<pub-id pub-id-type="pmid">37424174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1756-185X.14805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeshita</surname><given-names>J</given-names></name><name name-style="western"><surname>Chau</surname><given-names>J</given-names></name><name name-style="western"><surname>Duffin</surname><given-names>KC</given-names></name><name name-style="western"><surname>Goel</surname><given-names>N</given-names></name></person-group><article-title>Promoting diversity, equity, and inclusion for psoriatic diseases</article-title><source>J Rheumatol</source><year>2022</year><volume>49</volume><issue>6 Suppl 1</issue><fpage>48</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">35293335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.211330</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Takeshita J, Chau J, Duffin KC, Goel N. Promoting diversity, equity, and inclusion for psoriatic diseases. J Rheumatol. 2022;49(6 Suppl 1):48&#8211;51.<pub-id pub-id-type="pmid">35293335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.211330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>G</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>J</given-names></name><name name-style="western"><surname>Miller-Monthrope</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lakhani</surname><given-names>O</given-names></name><name name-style="western"><surname>Drudge</surname><given-names>C</given-names></name><name name-style="western"><surname>Craigie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Unmet need in people with psoriasis and skin of color in Canada and the United States</article-title><source>Dermatol Ther (Heidelb).</source><year>2022</year><volume>12</volume><issue>11</issue><fpage>2401</fpage><lpage>2413</lpage><pub-id pub-id-type="doi">10.1007/s13555-022-00811-0</pub-id><pub-id pub-id-type="pmid">36131193</pub-id><pub-id pub-id-type="pmcid">PMC9588130</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Yadav G, Yeung J, Miller-Monthrope Y, Lakhani O, Drudge C, Craigie S, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther (Heidelb). 2022;12(11):2401&#8211;13.<pub-id pub-id-type="pmid">36131193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13555-022-00811-0</pub-id><pub-id pub-id-type="pmcid">PMC9588130</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKenzie</surname><given-names>S</given-names></name><name name-style="western"><surname>Brown-Korsah</surname><given-names>JB</given-names></name><name name-style="western"><surname>Syder</surname><given-names>NC</given-names></name><name name-style="western"><surname>Omar</surname><given-names>D</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>SC</given-names></name><name name-style="western"><surname>Elbuluk</surname><given-names>N</given-names></name></person-group><article-title>Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color</article-title><source>J Am Acad Dermatol</source><year>2022</year><volume>87</volume><issue>6</issue><fpage>1261</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2022.03.067</pub-id><pub-id pub-id-type="pmid">35817332</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">McKenzie S, Brown-Korsah JB, Syder NC, Omar D, Taylor SC, Elbuluk N. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261&#8211;70.<pub-id pub-id-type="pmid">35817332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2022.03.067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>MY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Kingston</surname><given-names>P</given-names></name><name name-style="western"><surname>Yee</surname><given-names>D</given-names></name><name name-style="western"><surname>Korouri</surname><given-names>E</given-names></name><etal/></person-group><article-title>Comorbidity burden in psoriasis patients with skin of color</article-title><source>J Psoriasis Psoriatic Arthritis.</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1177/24755303231198482</pub-id><pub-id pub-id-type="pmid">38516030</pub-id><pub-id pub-id-type="pmcid">PMC10957134</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Peterson H, Huang MY, Lee K, Kingston P, Yee D, Korouri E, et al. Comorbidity burden in psoriasis patients with skin of color. J Psoriasis Psoriatic Arthritis. 2024;9(1):16&#8211;22.<pub-id pub-id-type="pmid">38516030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/24755303231198482</pub-id><pub-id pub-id-type="pmcid">PMC10957134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Fagni</surname><given-names>F</given-names></name><name name-style="western"><surname>Gossec</surname><given-names>L</given-names></name><name name-style="western"><surname>Giovannini</surname><given-names>I</given-names></name><name name-style="western"><surname>Sticherling</surname><given-names>M</given-names></name><name name-style="western"><surname>Tullio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage</article-title><source>RMD Open</source><year>2024</year><volume>10</volume><issue>2</issue><fpage>e004314</fpage><pub-id pub-id-type="doi">10.1136/rmdopen-2024-004314</pub-id><pub-id pub-id-type="pmid">38599649</pub-id><pub-id pub-id-type="pmcid">PMC11015289</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Zabotti A, Fagni F, Gossec L, Giovannini I, Sticherling M, Tullio A, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10(2): e004314.<pub-id pub-id-type="pmid">38599649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/rmdopen-2024-004314</pub-id><pub-id pub-id-type="pmcid">PMC11015289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Errichetti</surname><given-names>E</given-names></name><name name-style="western"><surname>Zabotti</surname><given-names>A</given-names></name></person-group><article-title>Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors</article-title><source>Dermatol Ther (Heidelb).</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1007/s13555-023-01072-1</pub-id><pub-id pub-id-type="pmid">38032434</pub-id><pub-id pub-id-type="pmcid">PMC10828264</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Errichetti E, Zabotti A. Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors. Dermatol Ther (Heidelb). 2024;14(1):1&#8211;3.<pub-id pub-id-type="pmid">38032434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13555-023-01072-1</pub-id><pub-id pub-id-type="pmcid">PMC10828264</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Floris A, Mugheddu C, Sichi L, Anedda J, Frau A, Sorgia J, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2024; p. keae257 (ahead of print).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keae257</pub-id><pub-id pub-id-type="pmid">38781521</pub-id></mixed-citation></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozince</surname><given-names>RB</given-names></name><name name-style="western"><surname>Ak</surname><given-names>T</given-names></name><name name-style="western"><surname>Erzin</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Melikoglu</surname><given-names>M</given-names></name><name name-style="western"><surname>Seyahi</surname><given-names>E</given-names></name></person-group><article-title>Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis</article-title><source>Int J Rheum Dis</source><year>2023</year><volume>26</volume><issue>9</issue><fpage>1811</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14667</pub-id><pub-id pub-id-type="pmid">36929128</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Ozince RB, Ak T, Erzin YZ, Melikoglu M, Seyahi E. Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis. Int J Rheum Dis. 2023;26(9):1811&#8211;5.<pub-id pub-id-type="pmid">36929128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1756-185X.14667</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>